<DOC>
	<DOCNO>NCT01364051</DOCNO>
	<brief_summary>This phase I trial study side effect best dose cediranib maleate selumetinib treat patient solid malignancy . Cediranib maleate selumetinib may stop growth tumor cell block enzymes need cell growth . Cediranib maleate may also stop growth tumor cell block blood flow tumor .</brief_summary>
	<brief_title>Cediranib Maleate Selumetinib Treating Patients With Solid Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose AZD2171 ( cediranib ) ( cediranib maleate ) combination AZD6244 hydrogen sulfate ( selumetinib ) . II . To describe toxicity profile associate AZD2171 ( cediranib ) combination AZD6244 hydrogen sulfate . III . To describe tumor response identify activity AZD2171 ( cediranib ) combination AZD6244 hydrogen sulfate . IV . To explore , correlative study , effect AZD2171 ( cediranib ) without AZD6244 hydrogen sulfate serum marker apoptosis . V. To assess pharmacokinetic interaction AZD2171 ( cediranib ) combination AZD6244 hydrogen sulfate . VI . To study association clinical ( toxicity and/or tumor response activity ) pharmacologic ( pharmacokinetic/pharmacodynamic ) parameter , and/or biologic ( correlative laboratory study ) result . OUTLINE : This dose-escalation study follow dose-expansion cohort study . Patients receive cediranib maleate orally ( PO ) daily ( QD ) selumetinib PO QD twice daily ( BID ) day 1-28 ( day 8-28 course 1 ) . Courses repeat every 28 day absence disease progression unacceptable toxicity . Courses may extend 12 week 1 year study treatment . After completion study therapy , patient follow 3 month .</detailed_description>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Histologic proof cancer consider clinically unresectable standard therapy ; NOTE : maximum tolerate dose ( MTD ) expansion cohort : metastatic melanoma histology require Measurable nonmeasurable disease eligible Ability provide inform consent Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelets ( PLT ) &gt; = 100,000/uL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) = &lt; 2.5 x ULN = &lt; 5 x ULN presence liver metastases Creatinine = &lt; 1.5 x ULN Hemoglobin ( HgB ) &gt; = 9.0 gm/dL Alkaline phosphatase = &lt; 2.5 x ULN Creatinine clearance &gt; 50 ml/min , either CockcroftGault formula 24hour urine collection analysis Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 Willing return Mayo follow Life expectancy &gt; = 12 week Women childbearing potential : negative serum pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Expansion phase : willing provide blood sample archive tumor tissue correlative research purpose Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Any follow prior therapy : Chemotherapy = &lt; 28 day prior registration Mitomycin C/nitrosoureas = &lt; 42 day prior registration Immunotherapy = &lt; 28 day prior registration Biologic therapy = &lt; 28 day prior registration Radiation therapy = &lt; 28 day prior registration Radiation &gt; 25 % bone marrow Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment Cardiac condition follow : Uncontrolled hypertension ( blood pressure [ BP ] &gt; = 150/95 despite optimal therapy ) Heart failure New York Heart Association ( NYHA ) class II leave ventricular ejection fraction &lt; 50 % Atrial fibrillation heart rate &gt; 100 bpm Unstable ischemic heart disease ( myocardial infarction [ MI ] within 6 month prior start treatment , angina require use nitrate weekly ) Patients require concomitant agent prolong correct QT interval ( QTc ) Known brain central nervous system ( CNS ) metastases without definitive therapy ; patient receive definitive therapy CNS lesion may consider evidence progression compute tomography ( CT ) magnetic resonance imaging ( MRI ) imaging obtain 3 month apart Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) exception patient know human immunodeficiency virus [ HIV ] positive cluster differentiation [ CD ] 4 count &gt; 400 require antiretroviral therapy Receiving investigational agent would consider treatment primary neoplasm Other active malignancy = &lt; 3 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinomainsitu cervix ; NOTE : history prior malignancy , must receive specific treatment ( i.e . hormonal therapy ) cancer Greater +1 proteinuria two consecutive dipstick take less 1 week apart unless urinary protein &lt; 1.5g 24 hour ( hr ) period urine protein/creatinine ratio &lt; 1.5 History exposure AZD2171 ( cediranib ) , AZD6244 hydrogen sulfate , mitogenactivated protein kinase kinase ( MEK ) , retrovirusassociated deoxyribonucleic acid ( DNA ) sequence ( Ras ) vRAF1 murine leukemia viral oncogene homolog ( Raf ) inhibitor ( sorafenib ) ; Note : prior therapy bevacizumab , sunitinib , pazopanib aflibercept ( vascular endothelial growth factor [ VEGF ] Trap ) allow Surgery within two week prior registration Significant hemorrhage ( &gt; 30 mL bleeding/episode previous 3 month ) hemoptysis ( &gt; 5 mL fresh blood previous 4 week ) Mean QTc interval Bazetts correction &gt; 480 msec ( Common Toxicity Criteria [ CTC ] grade 1 ) screen electrocardiogram ( ECG ) history familial long QT syndrome Patients unable swallow tablet capsule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>